Iovance Biotherapeutics, Inc. Stock price
Equities
IOVA
US4622601007
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.84 USD | +5.21% | -3.39% | +82.52% |
Financials (USD)
Sales 2024 * | 161M | Sales 2025 * | 413M | Capitalization | 3.94B |
---|---|---|---|---|---|
Net income 2024 * | -352M | Net income 2025 * | -245M | EV / Sales 2024 * | 23.6 x |
Net cash position 2024 * | 133M | Net cash position 2025 * | 251M | EV / Sales 2025 * | 8.93 x |
P/E ratio 2024 * |
-10.9
x | P/E ratio 2025 * |
-19.6
x | Employees | 557 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.71% |
Latest transcript on Iovance Biotherapeutics, Inc.
1 day | +0.36% | ||
1 week | -5.56% | ||
Current month | -11.38% | ||
1 month | -19.29% | ||
3 months | +95.02% | ||
6 months | +213.33% | ||
Current year | +73.43% |
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 16-09-29 |
Director of Finance/CFO | 51 | 20-12-13 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 11-07-19 |
Director/Board Member | 56 | 16-06-06 | |
Michael Weiser
BRD | Director/Board Member | 61 | 18-03-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 11 M€ | -6.03% | - | |
0.93% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.11% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 14.83 | +5.18% | 4 005 097 |
24-03-27 | 14.1 | +0.36% | 4,111,414 |
24-03-26 | 14.05 | -3.30% | 5,101,022 |
24-03-25 | 14.53 | -3.26% | 4,574,683 |
24-03-22 | 15.02 | -2.21% | 3,694,385 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.43% | 3.94B | |
-9.60% | 12.14B | |
-33.60% | 2.19B | |
-21.05% | 1.63B | |
+30.99% | 1.14B | |
+9.17% | 852M | |
-12.33% | 545M | |
-41.02% | 419M | |
+28.48% | 249M | |
+4.73% | 234M |